Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Hexaminolevulinate→

Hexaminolevulinate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
140898-97-1
Molecular formula
C11H21NO3
Molecular weight
215.29 g/mol
Drug class
Hexaminolevulinate hydrochlorideprodrug of 5-aminolevulinic acid for photodynamic diagnostic imaging
Mechanism of action
Converted intracellularly to porphyrin precursors, including fluorescent protoporphyrin IX, which accumulates preferentially in urothelial lesions. Under blue-light cystoscopy, fluorescent tissue is detected to aid visualisation of bladder lesions.
Indications / reported uses
  • Optical imaging of bladder cancer during blue-light cystoscopy in adults with known or suspected non-muscle-invasive bladder cancer, as an adjunct to white-light cystoscopy; not a stand-alone diagnostic test

Sources: US DailyMed — Cysview (hexaminolevulinate) · NLM MeSH — Hexaminolevulinate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Hexaminolevulinate Environmental Risk Assessment (ERA) (the Hexaminolevulinate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.